| pubmed-article:9023281 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9023281 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:9023281 | lifeskim:mentions | umls-concept:C0020542 | lld:lifeskim |
| pubmed-article:9023281 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:9023281 | lifeskim:mentions | umls-concept:C2266875 | lld:lifeskim |
| pubmed-article:9023281 | lifeskim:mentions | umls-concept:C1134681 | lld:lifeskim |
| pubmed-article:9023281 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9023281 | pubmed:dateCreated | 1997-3-17 | lld:pubmed |
| pubmed-article:9023281 | pubmed:abstractText | It has been proposed that endothelin-1 (ET-1), a potent endogenous vasoactive peptide, may play an important role in the regulation of pulmonary blood flow. The purpose of the present study was to characterize the effects of ET-1 and a nonpeptide mixed ET(A) and ET(B) receptor antagonist, SB 209670, in isolated segments of the canine pulmonary artery and to examine the effects of SB 209670 in a canine model of acute hypoxia-induced pulmonary hypertension. In isolated segments of the pulmonary artery, SB 209670 (3-300 nM) produced a concentration-dependent antagonism of contraction elicited by ET-1 (pA2 = 8.9; slope = 0.9) and had no effect on phenylephrine responses. In addition, SB 209670 antagonized the small, endothelium-dependent relaxation induced by sarafotoxin 6c in phenylephrine (10 microM)-precontracted vessels (pKB = 8.6). In anesthetized dogs, the driving pressure across the pulmonary circulation increased approximately 100% during the hypoxic period (area under the curve [AUC] = 267.1 +/- 25.3 mm Hg x min). SB 209670 treatment (3 and 30 microg/kg/min i.v.) reduced pulmonary vascular resistance and produced a profound dose-related inhibition of hypoxia-induced pulmonary hypertension (AUC = 158.3 +/- 22.7 mm Hg x min and 50.1 +/- 4.9 mm Hg x min, respectively). None of the other hemodynamic or arterial blood gas parameters differed significantly in the vehicle and treatment groups. In addition, SB 209670 produced a significant reversal of hypoxia-induced pulmonary hypertension (AUC = 267.1 +/- 25.3 mm Hg x min vs. 167.8 +/- 23.4 mm Hg x min) when administered at the plateau of the hypoxic response. It was found that SB 209670 administration significantly elevated plasma levels of ET-1-LI (> or = 25-fold). These results suggest that ET-1 is an important mediator of hypoxia-induced pulmonary hypertension in the dog and that SB 209670, a potent and selective mixed ET(A) and ET(B)receptor antagonist in the pulmonary circulation, may represent an important therapeutic approach to the treatment of pulmonary hypertension. | lld:pubmed |
| pubmed-article:9023281 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9023281 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9023281 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9023281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9023281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9023281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9023281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9023281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9023281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9023281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9023281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9023281 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9023281 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9023281 | pubmed:issn | 0022-3565 | lld:pubmed |
| pubmed-article:9023281 | pubmed:author | pubmed-author:OhlsteinE HEH | lld:pubmed |
| pubmed-article:9023281 | pubmed:author | pubmed-author:BeckG RGR | lld:pubmed |
| pubmed-article:9023281 | pubmed:author | pubmed-author:LIMT WTW | lld:pubmed |
| pubmed-article:9023281 | pubmed:author | pubmed-author:WilletteR NRN | lld:pubmed |
| pubmed-article:9023281 | pubmed:author | pubmed-author:SauermelchC... | lld:pubmed |
| pubmed-article:9023281 | pubmed:author | pubmed-author:MitchellM PMP | lld:pubmed |
| pubmed-article:9023281 | pubmed:author | pubmed-author:LuttmannM AMA | lld:pubmed |
| pubmed-article:9023281 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9023281 | pubmed:volume | 280 | lld:pubmed |
| pubmed-article:9023281 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9023281 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9023281 | pubmed:pagination | 695-701 | lld:pubmed |
| pubmed-article:9023281 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:meshHeading | pubmed-meshheading:9023281-... | lld:pubmed |
| pubmed-article:9023281 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9023281 | pubmed:articleTitle | Nonpeptide endothelin receptor antagonists. VIII: attentuation of acute hypoxia-induced pulmonary hypertension in the dog. | lld:pubmed |
| pubmed-article:9023281 | pubmed:affiliation | Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA. | lld:pubmed |
| pubmed-article:9023281 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9023281 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9023281 | lld:pubmed |
